Making cervical cancer elimination an achievable reality
In a country where cervical cancer claims countless lives not for lack of scientific knowledge but for lack of affordable access, India has crossed a meaningful threshold: its first domestically developed HPV screening test has been validated to international standards. Created by Goa-based Molbio Diagnostics and rigorously evaluated by AIIMS, ICMR, and the WHO's cancer research agency, the Truenat HPV-HR Plus test offers what imported tools never could — a price point and a supply chain suited to the villages and clinics where the need is greatest. The science of prevention has long existed; what changes now is who it can reach.
- Cervical cancer has persisted as a leading killer of Indian women precisely because the tools to detect it early were priced out of the public health systems serving the most vulnerable.
- Imported HPV tests created a quiet but devastating inequality — women near well-funded urban hospitals could be screened, while those hours away in rural areas largely could not.
- Molbio Diagnostics built and validated an indigenous alternative that matches global gold-standard performance, closing a gap that was never about science and always about economics.
- The validation by AIIMS, ICMR institutes, and WHO's IARC gives the test the credibility needed for adoption in national screening programmes — legitimacy that matters as much as affordability.
- With HPV vaccination programmes already expanding, this screening test completes the prevention equation for older women who were never vaccinated, making population-scale protection newly conceivable.
- The harder work now begins: whether the test travels from laboratory validation to rural clinic shelves will depend on political will, training, and public awareness — none of which are guaranteed.
India has validated its first domestically produced test for detecting high-risk strains of the human papillomavirus — the pathogen responsible for most cervical cancers. The achievement belongs to Molbio Diagnostics, a Goa-based company, whose Truenat HPV-HR Plus test was evaluated by researchers from AIIMS, multiple ICMR institutes, and the WHO's International Agency for Research on Cancer. The verdict: it performs at the level of the best screening tools used anywhere in the world.
The significance lies less in the science than in the economics. Cervical cancer is among the most common cancers affecting Indian women, yet screening rates have remained low for a simple reason — the imported tests that exist are too expensive for rural clinics and overstretched public health systems. A woman far from a major hospital has had little practical means of knowing whether she carries a dangerous HPV strain. Without that knowledge, precancerous changes go undetected, and cancer develops silently.
An indigenous test, manufactured locally and priced accordingly, changes that calculus. Large-scale screening programmes that were previously unaffordable become feasible. Molbio's chief executive, Sriram Natarajan, described the validation as a step toward making cervical cancer elimination achievable in India — part of a broader mission to bring molecular diagnostics within reach of populations long excluded by cost.
The timing is deliberate. As India expands its HPV vaccination programmes for younger girls, the new screening test addresses the gap for older women who were vaccinated too late or not at all. Vaccination and screening together form a coherent prevention strategy; this test makes the screening half viable at scale.
Validation, however, is a beginning rather than an end. Whether the test reaches the women who need it most — whether rural clinics stock it, whether health workers are trained, whether women are informed — depends on implementation choices still to be made. The pathway now exists. Walking it is the work ahead.
India has developed and validated its first domestically made test for detecting the human papillomavirus, the pathogen responsible for most cervical cancers. The achievement matters because it opens a path toward screening millions of women who have been locked out of early detection—not because the science was unavailable, but because the tools were too expensive and the infrastructure to run them too sparse.
Cervical cancer ranks among the most common malignancies affecting Indian women. Yet screening rates have remained stubbornly low. The imported HPV tests that do exist carry price tags that place them beyond reach for rural clinics and smaller healthcare facilities. A woman in a village two hours from the nearest city hospital has had little practical way to know whether she carries a high-risk strain of the virus. Without that knowledge, she cannot be monitored. Without monitoring, precancerous changes go undetected. Without detection, cancer develops.
The new test, called Truenat HPV-HR Plus, was developed by Molbio Diagnostics, a company based in Goa. It identifies the high-risk variants of HPV most likely to trigger malignant transformation. The validation process involved researchers from the All India Institute of Medical Sciences, multiple institutes under the Indian Council of Medical Research, and scientists from the World Health Organization's International Agency for Research on Cancer. That collaboration produced a rigorous evaluation confirming the test performs at the same level as the gold-standard screening tools used globally. It meets international quality benchmarks. It works.
What makes this breakthrough significant is not the novelty of the science—HPV screening itself is well understood—but the economics and accessibility. An imported test represents a substantial cost to a public health system already stretched thin. An indigenous alternative, manufactured locally and priced accordingly, can be deployed at scale. Large screening programs become feasible. Women in underserved areas gain access to the same detection capability that has long existed for wealthier populations.
Sriram Natarajan, the chief executive of Molbio Diagnostics, framed the validation as a step toward making cervical cancer elimination achievable in India. He emphasized that the company's mission centers on democratizing access to molecular diagnostics—making sophisticated testing available not just to those who can afford premium prices, but to public health systems serving populations with limited resources.
The timing aligns with India's expanding HPV vaccination programs. As more girls receive the vaccine, the new screening test will help identify infections in older women who were vaccinated too late or not at all. Together, vaccination and screening form a two-pronged prevention strategy. The test enables the second prong to function at population scale.
What comes next is implementation. Validation is the prerequisite, not the endpoint. The real measure of success will be whether this test actually reaches the women who need it—whether rural clinics stock it, whether public health workers are trained to use it, whether women are informed and encouraged to get screened. The pathway exists now. Whether India walks it depends on decisions yet to be made.
Citas Notables
With the validation of Truenat HPV-HR Plus, India takes an important step towards making cervical cancer elimination an achievable reality. This milestone demonstrates the power of indigenous innovation to deliver globally validated solutions that can expand access to screening, strengthen public health programmes, and ultimately save lives.— Sriram Natarajan, Chief Executive Officer of Molbio Diagnostics
La Conversación del Hearth Otra perspectiva de la historia
Why does an indigenous test matter so much if the science of HPV screening already exists?
Because science and access are different things. A test that costs too much to run at scale is a test that doesn't reach the people who need it most. This one can be manufactured and deployed locally, which changes the economics entirely.
What makes this test specifically suited to India's healthcare landscape?
It was designed with India's constraints in mind—the reality that many clinics lack advanced laboratory infrastructure, that budgets are tight, that distances are vast. It uses molecular diagnostics but doesn't require the same level of facility complexity as imported alternatives.
How confident are experts that this will actually change screening rates?
The validation proves the test works. But screening rates depend on whether it's actually available where women are, whether they know about it, whether they can access it without traveling hours. The test is necessary but not sufficient.
What's the connection between this test and the vaccination programs you mentioned?
Vaccination prevents new infections in younger women. Screening catches existing infections in older women before they become cancer. Together they create a complete prevention strategy—but only if both are actually deployed.
Who benefits most from this development?
Women in rural and underserved areas who have had no practical way to know their HPV status. Also the public health systems serving them, which can now offer screening without importing expensive tests.
What's the risk of this becoming just another tool that sits on a shelf?
That's the real question. Validation is the easy part. Implementation—getting it into clinics, training people to use it, ensuring women actually get tested—that's where the work really happens.